AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) Files An 8-K Entry into a Material Definitive Agreement

AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry Into a Material Definitive Agreement.

Story continues below

On February 22, 2019 and February 25, 2019, Amicus Therapeutics, Inc. (the “Company”) entered into separate, privately negotiated agreements (the “Agreements”) with Goldman Sachs & Co., JP Morgan Chase Bank, National Association and Royal Bank of Canada (collectively, the “Counterparties”) relating to the privately negotiated capped call transactions entered into on December 15, 2016 (the “Base Capped Call Transactions”) and the over-allotment option granted and entered into with the Counterparties on December 16, 2016 (the “Additional Capped Call Transactions”, together with the Base Capped Call Transactions, the “Capped Call Transactions”). The Capped Call Transactions were entered into in connection with the Company’s issuance of their 3.00% Convertible Senior Notes due 2023, issued on December 21, 2016. A summary of the material terms of the Capped Call Transactions was included in the Company’s Current Report on Form 8-K filed on December 21, 2016, which is incorporated herein by reference and is qualified in its entirety by reference to the full text of the Capped Call Transactions filed as exhibits thereto.

Per the terms of the Agreements, the base amount payable under the Base Capped Call Transactions by the Counterparties has been reduced and the Additional Capped Call Transactions with JP Morgan Chase Bank, National Association and Royal Bank of Canada have been terminated in consideration for an aggregate cash payment of approximately $14.6 million, as calculated by the interday Volume Weighted Average Price. Following the amendments, the Counterparties remain parties to the Base Capped Call Transactions.

There are no relationships with the Counterparties other than those disclosed above.

Item 1.02 Termination of a Material Definitive Agreement.

The information contained in Item 1.01 is incorporated herein by reference.


Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.

An ad to help with our costs